Gram-positive Bacterial Infections Market 2028 By Disease, Drug Type, Route of Administration, Distribution Channel and Geography | The Insight Partners

report image

Gram-positive Bacterial Infections Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease (Methicillin-resistant Staphylococcus aureus (MRSA), Pneumonia, Sepsis, Sinusitis, Skin Disorders, Other Diseases); Drug Type (Antibiotic, Antifungal, Others); Route of Administration (Enteral, Parenteral, Others); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Other Distribution Channels) and Geography

Report Code: TIPRE00004059 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Gram-positive bacteria are known as the leading class of bacteria to cause infectious diseases in humans. These bacteria retain gram stain because of which are observed as violet purple colored stains when observed under the microscope. Infections caused due to gram positive bacteria are acquired through various source. They are known to cause infections such as,sepsis, pneumonia, and MRSA, among others. Because of their highly infectious nature, treatment of gram positive infections has been an area of focus during the recent years. And various approches are been developed to manage infections caused due to gram positive bacteria.


The "Global Gram-Positive Bacterial Infections Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the gram-positive bacterial infections market with detailed market segmentation by disease, drug type, route of administration and distribution channel. The report provides key statistics on the market status of the leading gram-positive bacterial infections market players and offers key trends and opportunities in the market.


  •   Based on disease the market is segmented as, Methicillin-Resistant Staphylococcus Aureus (MRSA), pneumonia, sepsis, sinusitis, skin disorders and other diseases.
  •   Based on drug type the market is segmented as, antibiotic, antifungal and others.
  •   Based on route of administration the market is segmented as, enteral, parenteral and others.
  •   Based on distribution channel the market is segmented as, hospital pharmacies, drug stores and retail pharmacies and other distribution channels.



  •   Increasing prevalence of infections caused by gram positive bacteria.
  •   Increasing awareness regarding management of infectious diseases.
  •   Ongoing R&D studies by pharmaceutical companies to develop therapies for management of gram positive bacterial infections.


  •   However, risk of side effects due to prolonged drug therapy is likely to restrain market growth during the forecast period.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The gram-positive bacterial infections market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the gram-positive bacterial infections market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.


The report covers key developments in the gram-positive bacterial infections market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from gram-positive bacterial infections market are anticipated to lucrative growth opportunities in the future with the rising demand for gram-positive bacterial infections in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the gram-positive bacterial infections market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  •   Abbvie
  •   AstraZeneca
  •   Bayer AG
  •   GlaxoSmithKline plc.
  •   Merck Sharp and Dohme Corp.
  •   NovaBiotics Ltd
  •   Novartis AG
  •   Pfizer Inc.
  •   Sanofi
  •   Dr. Reddy's Laboratories Inc
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • The List of Companies

    - Abbvie
    - AstraZeneca
    - Bayer AG
    - GlaxoSmithKline plc.
    - Merck Sharp and Dohme Corp.
    - NovaBiotics Ltd
    - Novartis AG
    - Pfizer Inc.
    - Sanofi
    - Dr. Reddy's Laboratories Inc
    - Cipla
    - Alembic Pharmaceuticals
    - Mankind Pharma
    - Intas
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market

    Have a Question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

    Speak to Analyst
    • $3000
    • $4550
    • $6550
    • $8550

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount